Evidence map›Paper›PMID 39996765›Full record

ReviewCells2025

Shaping Rare Granulomatous Diseases in the Lab: How New Models Are Changing the Game.

Jessica Ceccato, Giulia Gualtiero, Maria Piazza, Samuela Carraro, Helena Buso, Carla Felice, Marcello Rattazzi, Riccardo Scarpa, Fabrizio Vianello, Francesco Cinetto

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica CeccatoHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy.
Giulia GualtieroHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy.ORCID 0009-0001-4160-0091
Maria PiazzaDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.ORCID 0000-0002-6640-5401
Samuela CarraroRare Diseases Referral Center, Internal Medicine 1, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, 31100 Treviso, Italy.ORCID 0009-0005-7373-9695
Helena BusoDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.
Carla FeliceDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.
Marcello RattazziDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.
Riccardo ScarpaDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.ORCID 0000-0002-1085-2333
Fabrizio VianelloHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy.ORCID 0000-0002-7174-4651
Francesco CinettoDepartment of Medicine (DIMED), University of Padua, 35128 Padua, Italy.ORCID 0000-0001-8486-5850

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro models serve as valuable tools for understanding the complex cellular and molecular interactions involved in granuloma formation, providing a controlled environment to explore the underlying mechanisms of their development and function. Various models have been developed to replicate granulomatous diseases, even though they may lack the sophistication needed to fully capture the variability present in clinical spectra and environmental influences. Traditional cultures of PBMCs have been widely used to generate granuloma models, enabling the study of aggregation responses to various stimuli. However, growing cells on a two-dimensional (2D) plastic surface as a monolayer can lead to altered cellular responses and the modulation of signaling pathways, which may not accurately represent in vivo conditions. In response to these limitations, the past decade has seen significant advancements in the development of three-dimensional (3D) in vitro models, which more effectively mimic in vivo conditions and provide better insights into cell-cell and cell-microenvironment interactions. Meanwhile, the use of in vivo animal models in biomedical research must adhere to the principle of the three Rs (replacement, reduction, and refinement) while ensuring that the models faithfully replicate human-specific processes. This review summarizes and compares the main models developed to investigate granulomas, focusing on their contribution to advancing our understanding of granuloma biology. We also discuss the strengths and limitations of each model, offering insights into their biological relevance and practical applications.

Indexed as

GranulomaModels, BiologicalRare DiseasesAnimalsDisease Models, AnimalHumans3D modelsgranulomainterstitial lung diseasemultinucleated giant cellssarcoidosis

Identifiers

PMID39996765
PMCPMC11853845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.